Neurology
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

This Article
Right arrow Figures Only
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Correspondence:
Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when Correspondence are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Herukka, S.-K.
Right arrow Articles by Pirttilä, T.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Herukka, S.-K.
Right arrow Articles by Pirttilä, T.
Related Collections
Right arrow Alzheimer's disease
Right arrow MCI (mild cognitive impairment)
NEUROLOGY 2005;64:1294-1297
© 2005 American Academy of Neurology
Brief Communications

CSF Aß42 and tau or phosphorylated tau and prediction of progressive mild cognitive impairment

Sanna-Kaisa Herukka, Merja Hallikainen, MD, PhD, Hilkka Soininen, MD, PhD and Tuula Pirttilä, MD, PhD

From the Department of Neuroscience and Neurology (Drs. Hallikainen, Soininen, and Pirttilä, S.-K. Herukka), University of Kuopio, and Department of Neurology (Drs. Soininen and Pirttilä), Kuopio University Hospital, Finland.

Address correspondence and reprint requests to Dr. T. Pirttilä, Department of Neurology, Kuopio University Hospital, 70211 Kuopio, Finland; e-mail: tuula.pirttila{at}kuh.fi

Baseline CSF amyloid ß-peptide-42 (Aß42), tau, and phosphorylated tau (P-tau) levels from 46 control subjects and 78 patients with mild cognitive impairment (MCI) were measured. Twenty-three patients with MCI developed dementia during the study. Abnormal biomarkers were found early in the course of Alzheimer disease (AD). The most predictive assay for AD among the patients with MCI was the combination of Aß42 and P-tau.

Supported by the Kuopio University Hospital (EVO grant nos. 5772720 and 5772725).

Received June 3, 2004. Accepted in final form December 14, 2004.




This article has been cited by other articles:


Home page
 J. Neurol. Neurosurg. PsychiatryHome page
A J Mitchell
CSF phosphorylated tau in the diagnosis and prognosis of mild cognitive impairment and Alzheimer's disease: a meta-analysis of 51 studies
J. Neurol. Neurosurg. Psychiatry, September 1, 2009; 80(9): 966 - 975.
[Abstract] [Full Text] [PDF]

Home page
 JAMAHome page
N. Mattsson, H. Zetterberg, O. Hansson, N. Andreasen, L. Parnetti, M. Jonsson, S.-K. Herukka, W. M. van der Flier, M. A. Blankenstein, M. Ewers, et al.
CSF Biomarkers and Incipient Alzheimer Disease in Patients With Mild Cognitive Impairment
JAMA, July 22, 2009; 302(4): 385 - 393.
[Abstract] [Full Text] [PDF]

Home page
 Arch NeurolHome page
B. J. Snider, A. M. Fagan, C. Roe, A. R. Shah, E. A. Grant, C. Xiong, J. C. Morris, and D. M. Holtzman
Cerebrospinal Fluid Biomarkers and Rate of Cognitive Decline in Very Mild Dementia of the Alzheimer Type
Arch Neurol, May 1, 2009; 66(5): 638 - 645.
[Abstract] [Full Text] [PDF]

Home page
 Arch NeurolHome page
T. Tapiola, I. Alafuzoff, S.-K. Herukka, L. Parkkinen, P. Hartikainen, H. Soininen, and T. Pirttila
Cerebrospinal Fluid {beta}-Amyloid 42 and Tau Proteins as Biomarkers of Alzheimer-Type Pathologic Changes in the Brain
Arch Neurol, March 1, 2009; 66(3): 382 - 389.
[Abstract] [Full Text] [PDF]

Home page
 NeurologyHome page
J. M. Ringman, S. G. Younkin, D. Pratico, W. Seltzer, G. M. Cole, D. H. Geschwind, Y. Rodriguez-Agudelo, B. Schaffer, J. Fein, S. Sokolow, et al.
Biochemical markers in persons with preclinical familial Alzheimer disease
Neurology, July 8, 2008; 71(2): 85 - 92.
[Abstract] [Full Text] [PDF]

Home page
 NeurologyHome page
M. Ewers, K. Buerger, S. J. Teipel, P. Scheltens, J. Schroder, R. P. Zinkowski, F. H. Bouwman, P. Schonknecht, N.S.M. Schoonenboom, N. Andreasen, et al.
Multicenter assessment of CSF-phosphorylated tau for the prediction of conversion of MCI
Neurology, December 11, 2007; 69(24): 2205 - 2212.
[Abstract] [Full Text] [PDF]

Home page
 NeurologyHome page
F. H. Bouwman, W. M. van der Flier, N.S.M. Schoonenboom, E. J. van Elk, A. Kok, F. Rijmen, M. A. Blankenstein, and P. Scheltens
Longitudinal changes of CSF biomarkers in memory clinic patients
Neurology, September 4, 2007; 69(10): 1006 - 1011.
[Abstract] [Full Text] [PDF]

Home page
 NeurologyHome page
N. M. Kemppainen, S. Aalto, I. A. Wilson, K. Nagren, S. Helin, A. Bruck, V. Oikonen, M. Kailajarvi, M. Scheinin, M. Viitanen, et al.
PET amyloid ligand [11C]PIB uptake is increased in mild cognitive impairment
Neurology, May 8, 2007; 68(19): 1603 - 1606.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Chem.Home page
T. S.M. Reijn, M. O. Rikkert, W. J.A. van Geel, D. de Jong, and M. M. Verbeek
Diagnostic Accuracy of ELISA and xMAP Technology for Analysis of Amyloid {beta}42 and Tau Proteins
Clin. Chem., May 1, 2007; 53(5): 859 - 865.
[Abstract] [Full Text] [PDF]

Home page
 Arch NeurolHome page
A. M. Fagan, C. M. Roe, C. Xiong, M. A. Mintun, J. C. Morris, and D. M. Holtzman
Cerebrospinal Fluid tau/beta-Amyloid42 Ratio as a Prediction of Cognitive Decline in Nondemented Older Adults
Arch Neurol, March 1, 2007; 64(3): 343 - 349.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 2005 by AAN Enterprises, Inc.